Not blinding sampling times [Bioanalytics]

posted by Obinoscopy  – USA, 2018-08-19 20:20 (887 d 23:51 ago) – Posting: # 19177
Views: 2,433

Hi Helmut,

» Even if substantial carry-over is not apparent in method validation (which would call for injecting mobile phase between samples), it exists. The EMA’s GL tells us [...]

Going by that guideline, will it be safe to say that the converse it also true. That is:

If it appears there is no carry-over, study samples should be randomised


Well, just as you said, carryover is always very likely. Thus complete randomisation will not be the reasonable path to follow.

Thanks guys, at least I am glad I let my thoughts out and not get drowned in them.

Scopy

Complete thread:

Activity
 Admin contact
21,310 posts in 4,445 threads, 1,489 registered users;
online 5 (0 registered, 5 guests [including 2 identified bots]).
Forum time: Saturday 20:12 UTC (Europe/Vienna)

Any sufficiently advanced technology
is indistinguishable from magic.    Arthur C. Clarke

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5